How Microdosing Psilocybin and LSD Helped a Grieving Mother Cope with the Loss of Her Son

Core Concepts

Microdosing psilocybin and LSD helped the author navigate the grief and loss after the death of her 18-year-old son.

Abstract

The author, Aracelly Bibl, describes how the death of her 18-year-old son left an enormous void in her heart that felt impossible to fill. In her quest for acceptance, she turned to the underground world of psychedelic-assisted therapy, specifically the practice of microdosing psilocybin and LSD.
Microdosing involves taking sub-perceptual doses of psychedelics, which are believed to provide therapeutic benefits without the full psychedelic experience. The author found that microdosing helped her cope with the grief and loss, allowing her to process her emotions and gain a new perspective on her life.
The author explains that the psychedelics helped her access deeper levels of self-awareness and emotional processing, enabling her to work through the trauma and pain of losing her son. She found that the microdoses provided a sense of clarity and calm, allowing her to navigate the grieving process more effectively.
The author emphasizes that the use of psychedelics in this context was done in a responsible and thoughtful manner, with the guidance of a trusted therapist. She cautions that the use of these substances should be approached with care and under the supervision of a qualified professional.

Stats

None.

Quotes

"The death of my 18-year-old son left an enormous void in my heart that felt impossible to fill."
"In my quest for acceptance, I once again turned to the underground world of psychedelic-assisted therapy, specifically to the practice of microdosing, so that I could..."

Key Insights Distilled From

50% Better: Microdosing Psilocybin And LSD

by Aracelly Bib... at medium.com 05-29-2024

https://medium.com/@aracellybibl/50-better-microdosing-psilocybin-and-lsd-72d1744fe8cf

Deeper Inquiries

How can the therapeutic potential of microdosing psychedelics be further explored and validated through clinical research?

To further explore and validate the therapeutic potential of microdosing psychedelics, rigorous clinical research studies need to be conducted. These studies should follow a double-blind, placebo-controlled design to ensure the reliability of the results. Researchers can investigate the effects of microdosing on specific mental health conditions such as depression, anxiety, PTSD, and addiction. Longitudinal studies can track the long-term effects of microdosing on individuals' mental health and well-being. Additionally, neuroimaging techniques can be used to understand the neural mechanisms underlying the therapeutic effects of microdosing psychedelics. Collaboration between researchers, clinicians, and regulatory bodies is essential to design and conduct high-quality studies that can provide valuable insights into the therapeutic potential of microdosing psychedelics.

What are the potential risks and ethical considerations surrounding the use of psychedelics, even in a therapeutic context?

Despite their therapeutic potential, the use of psychedelics, including microdosing, comes with potential risks and ethical considerations. Psychedelics can induce intense psychological experiences that may be challenging for some individuals to navigate, leading to adverse reactions such as anxiety, paranoia, or psychosis. There is also a risk of substance abuse and dependence, especially if psychedelics are not used under proper supervision. Ethical considerations include issues related to informed consent, confidentiality, and the potential for coercion in therapeutic settings. Ensuring that individuals have access to accurate information about the risks and benefits of psychedelics, obtaining informed consent, and providing adequate support and monitoring during psychedelic-assisted therapy sessions are crucial to mitigating these risks and upholding ethical standards.

How can the integration of psychedelic-assisted therapy be made more accessible and available to those in need, while ensuring proper safeguards and oversight?

To make psychedelic-assisted therapy more accessible and available to those in need, several steps can be taken while ensuring proper safeguards and oversight. First, education and training programs can be developed to equip mental health professionals with the knowledge and skills needed to conduct psychedelic-assisted therapy safely and effectively. Public awareness campaigns can help reduce stigma and misinformation surrounding psychedelics, making it easier for individuals to seek out this form of therapy. Collaboration between researchers, clinicians, and policymakers can lead to the development of guidelines and regulations that ensure the ethical and responsible use of psychedelics in therapeutic settings. Establishing specialized clinics or centers dedicated to psychedelic-assisted therapy can provide a safe and supportive environment for individuals undergoing treatment. Overall, a multi-faceted approach that combines education, advocacy, regulation, and infrastructure development is essential to expanding access to psychedelic-assisted therapy while maintaining appropriate safeguards and oversight.